EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effectiveness and cost‐effectiveness of an app and rewards‐based intervention in type 2 diabetes: A randomised controlled trial

Eric Andrew Finkelstein iD, Daphne Su-Lyn Gardner iD, Kwang Wei Tham iD, Mihir Gandhi iD, Yin Bun Cheung iD, Joann Bairavi iD, Chun Fan Lee iD, Ngiap Chuan Tan iD, Ester Yeoh iD, Phong Ching Lee iD, Emily Tse Lin Ho, Thofique Adamjee und 2 weitere

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16067 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Eric Andrew Finkelstein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Health Services & Systems Research, Duke-NUS Medical School, Singapore, Singapore. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cost-Benefit Analysis, Mobile Applications, Reward. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Digital health interventions and economic incentives have shown promise in facilitating diabetes self‐management, though evidence is limited. Therefore, this study aimed to evaluate the effectiveness and cost‐effectiveness of a comprehensive app‐based diabetes self‐management programme with rewards for healthy behaviours and health outcomes. Materials and Methods The TRIal to slow the Progression Of Diabetes (TRIPOD) study was an open‐label, parallel‐group, randomised controlled trial conducted at Duke‐NUS Medical School, Singapore. Adults with Type 2 Diabetes (diabetes), HbA 1c of 7.5%‐11.0% (inclusive) and taking at least one oral diabetes medication were eligible. In total, 269 participants were randomised across three arms [Usual care (UC): 117, diabetes management programme (DMP) (intervention without rewards): 36, DMP+ (intervention with rewards): 116]. Data were analysed using intention‐to‐treat analysis with change in HbA 1c at month 12 between DMP+ and UC as the primary outcome. Cost‐effectiveness of DMP+ relative to UC was also calculated.

Results

Mean HbA 1c improved by 0.1% in UC and by 0.5% in DMP+ at 12 months, revealing a mean difference of 0.4% (95% confidence interval (CI): −0.70, −0.08, p = 0.015). The odds ratio of HbA 1c improvements of >0.5% was 2.12 (95% CI: 1.17, 3.85, p = 0.013) for DMP+ relative to UC. The incremental cost‐effectiveness ratio of DMP+ relative to UC was SGD8,516 (USD6,531) per quality‐adjusted life year gained if effectiveness could be maintained with a single year of intervention.

Conclusions

A comprehensive app‐based diabetes self‐management programme with rewards for healthy behaviours and health outcomes (DMP+) cost‐effectively improved glycaemic control in Type 2 diabetes patients. Organizations focusing on value‐based healthcare should consider subsidising similar interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cost-Benefit AnalysisMobile ApplicationsRewardSelf-ManagementGlycated HemoglobinHumansMaleFemaleMiddle AgedAgedSingaporeTreatment OutcomeAdultHealth BehaviorQuality-Adjusted Life Years

Stichwörter der Autor:innen

cost‐effectivenesseffectivenessglycaemic controlrandomised trialtype 2 diabetes

Substanzen

Glycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Health Services & Systems Research, Duke-NUS Medical School, Singapore, Singapore.
  • Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
  • Endocrinology Services, Woodlands Health, Singapore, Singapore.
  • Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore.
  • Department of Biostatistics, Singapore Clinical Research Institute, Singapore, Singapore.
  • Department of Research, SingHealth Polyclinics, Singapore, Singapore.

ORCID-Profile: Eric Andrew Finkelstein, Daphne Su-Lyn Gardner, Kwang Wei Tham, Mihir Gandhi, Yin Bun Cheung, Joann Bairavi, Chun Fan Lee, Ngiap Chuan Tan, Ester Yeoh, Phong Ching Lee, Yong Mong Bee, Su-Yen Goh

Förderung

  • National Medical Research Council

Zitieren

APA

Finkelstein, E. A., Gardner, D. S., Tham, K. W., Gandhi, M., Cheung, Y. B., Bairavi, J., Lee, C. F., Tan, N. C., Yeoh, E., Lee, P. C., Ho, E. T. L., Adamjee, T., Bee, Y. M., & Goh, S. Y. (2025). Effectiveness and cost‐effectiveness of an app and rewards‐based intervention in type 2 diabetes: A randomised controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16067

Vancouver

Finkelstein EA, Gardner DS, Tham KW, Gandhi M, Cheung YB, Bairavi J, et al. Effectiveness and cost‐effectiveness of an app and rewards‐based intervention in type 2 diabetes: A randomised controlled trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16067

BibTeX
@article{Finkelstein2025,
  author = {Finkelstein, Eric Andrew and Gardner, Daphne Su-Lyn and Tham, Kwang Wei and Gandhi, Mihir and Cheung, Yin Bun and Bairavi, Joann and Lee, Chun Fan and Tan, Ngiap Chuan and Yeoh, Ester and Lee, Phong Ching and Ho, Emily Tse Lin and Adamjee, Thofique and Bee, Yong Mong and Goh, Su-Yen},
  title = {Effectiveness and cost‐effectiveness of an app and rewards‐based intervention in type 2 diabetes: A randomised controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16067}
}
Kostenlos starten →